Equities

Outlook Therapeutics Inc

Outlook Therapeutics Inc

Actions
  • Price (EUR)5.40
  • Today's Change0.00 / 0.00%
  • Shares traded1.25k
  • 1 Year change+31.07%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments231714
Total Receivables, Net------
Total Inventory------
Prepaid expenses7.59107.03
Other current assets, total------
Total current assets312822
Property, plant & equipment, net0.030.070.28
Goodwill, net------
Intangibles, net------
Long term investments0.790.800.85
Note receivable - long term------
Other long term assets0.500.130.17
Total assets322923
LIABILITIES
Accounts payable6.573.492.20
Accrued expenses2.753.451.77
Notes payable/short-term debt000
Current portion long-term debt/capital leases36110.93
Other current liabilities, total1.861.861.86
Total current liabilities47206.75
Total long term debt00.0011
Total debt361112
Deferred income tax------
Minority interest------
Other liabilities, total0.010.060.55
Total liabilities472018
SHAREHOLDERS EQUITY
Common stock2.602.271.76
Additional paid-in capital451415346
Retained earnings (accumulated deficit)(468)(409)(343)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(14)8.744.61
Total liabilities & shareholders' equity322923
Total common shares outstanding13118.82
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.